With prescriptions for semaglutide drugs, including Wegovy and Ozempic, on the rise, food sellers are increasingly fielding questions about the possibility of a significant shift in how — or how much — people eat.

Most of the increasingly popular drugs work by reducing patients’ appetites. Food companies may face serious trouble as 1.7% of Americans are prescribed semaglutide drugs in 2023 – a 40-fold increase.

Currently, they seem to be approaching these drugs the same way they approach food fads: keeping an eye on consumer behavior and taking advantage of trends. However, some industry analysts say they need to take this class of drugs more seriously than fad diets.

CEO Sean Connolly said the company would adjust as needed if customers ate less or wanted different types of food during a call with Wall Street analysts on Thursday.

According to him, if they switch to different types of nutrients, we switch to different types of nutrients as well. Healthy Choice, Duncan Hines, and Marie Callender’s are among the food brands owned by Conagra. “If they change the kind of snacks they snack on, we’ll change that.” Conagra has a wide portfolio of food brands.

It is not a new approach to take this type of approach. As consumer trends change, big food companies are constantly adapting their products. In order to appeal to health-conscious consumers, companies have already tweaked their products to appeal to those taking semaglutide drugs.

For customers who want to control portion size (or who want to spend less), PepsiCo and Coca-Cola offer smaller products. The term “diet” is gradually being replaced by “zero sugar” in the branding of soda companies. Major brands, such as Mondelez, acquire smaller, trendier ones to stay on top of rapidly changing tastes.